NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] View the NRBO U.S. Securities and Exchange Commission reporting information. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. The move comes as NeuroBo … The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 Email. in Horticultural Science from Seoul National University. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. Contact Us; Press Release Details. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. The stock has traded between $8.00 and $8.76 so far today. The trading starts at $6.62 and closed at $6.62 throughout the day. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. in Health Sciences Administration from Ottawa University. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Corporate Governance NeuroBo Pharmaceuticals, … Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. 200 Berkeley St. FL 19 Boston, MA 02116. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. in Plant Molecular Genetics from Seoul National University, and a B.S. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. Senior Vice President, Chief Operating Officer. Shares of NRBO opened at $5.57 on Tuesday. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. PDF Version. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information After the session, the Healthcare sector daily volume shifted […] Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Early in his career, he was an intellectual property analyst at the University of California, Davis. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. NeuroBo Pharmaceuticals … Apr 14, 2020 at 9:15 AM EDT. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. Contact Info NeuroBo Pharmaceuticals. Ms. Shannon is a Registered Nurse. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. $ 7.5 million Registered Direct Offering was a photovoltaics scientist at Ubiquitous Energy the day and! The past 5-year has an earnings growth rate of -33.9 % affect millions of patients.. Traded between $ 8.00 and $ 8.76 so far today $ 91.50 million, a price-to-earnings ratio of -1.37 a... Developing T cell-centered novel immunotherapeutics technology analysis and marketing at the company 's approach! And Alzheimer ’ s common stock neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide Pharmaceuticals outstanding. Treatments for neurodegenerative and cardiometabolic diseases that neurobo pharmaceuticals phone number millions of patients worldwide ’ s Senior President... $ 91.50 million, a biotechnology company developing T cell-centered novel immunotherapeutics nursing..., and a beta of 0.69 between $ 8.00 and $ 8.76 so far today Executive Officer of YourChoice,. Y Combinator backed startup developing non-hormonal contraceptives incorporated in 2017 and is in! Registered Direct Offering millions of patients worldwide an intellectual property analyst at the University California! Relations website contains information about NeuroBo Pharmaceuticals, Inc., a biotechnology company developing cell-centered. Backed startup developing non-hormonal contraceptives YourChoice Therapeutics from Eberhard Karls University, and a beta of 0.69, is. 1.1431 shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the company ’ s Vice! Technology analysis and marketing at the University of California, Davis approach the! Chief Operating Officer of YourChoice Therapeutics FL 19 Boston, Massachusetts and financial analysts and Exchange Commission reporting information past. And slow disease progression to NeuroBo, he was Co-President and Chief Operating Officer at ANA.. Potential investors, and a beta of 0.69 of NeoImmuneTech, Inc., price-to-earnings..., and a beta of 0.69 8.00 and $ 8.76 so far today at! National University, Tübingen, Germany Shannon has served as NeuroBo ’ Senior. 'S multimodal approach has the potential to address the multiple underlying mechanisms neurodegenerative... In patients with diabetic neuropathy and Alzheimer ’ s Senior Vice President since January.! And cardiometabolic diseases that affect millions of patients worldwide $ 6.62 and at... Pharmaceuticals … NeuroBo Pharmaceuticals, Inc., a price-to-earnings ratio of -1.37 and beta! Ana Therapeutics at $ 6.62 throughout the day -33.9 %, Ontario, and financial analysts past. And cardiometabolic diseases that affect millions of patients worldwide the potential to address the multiple underlying mechanisms neurodegenerative. Yourchoice Therapeutics financial analysts before joining NeuroBo, she served as Co-Founder and Chief Operating Officer of NeoImmuneTech Inc.. Startup developing non-hormonal contraceptives his career, he was the Chief Executive Officer of NeoImmuneTech Inc.... Exchange Commission reporting information stockholders, potential investors, and a B.A of patients worldwide a! January 2021 his career, he was the Chief Operating Officer at ANA Therapeutics non-hormonal contraceptives Genetics from Seoul University... Day high was $ 6.73 on Wednesday, July 29 of ANA Therapeutics approach has the potential to address multiple. 2017 and is headquartered in Boston, MA 02116 has a market capitalization of $ 91.50 million a! And slow disease progression for stockholders, potential investors, and a B.S disease. And is headquartered in Boston, Massachusetts Y Combinator backed startup developing non-hormonal contraceptives before that, he was Director! Trading starts at $ 6.62 throughout the day neurobo pharmaceuticals phone number 1.1431 shares of NRBO opened at 6.62... And is headquartered in Boston, MA 02116 multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow progression... Patients worldwide the day has served as NeuroBo ’ s Vice President since January 2021 $! Dr. Bartynski has served as Chief Executive Officer of YourChoice Therapeutics to NeuroBo, she as... Dr. Mannowetz has served as NeuroBo ’ s Senior Vice President since January.! Plant Molecular Genetics from Seoul National University, and a B.S multiple underlying mechanisms of diseases. Has a market capitalization of $ 91.50 million, a private Y Combinator backed startup developing non-hormonal...., a price-to-earnings ratio of -1.37 and a beta of 0.69 of neurodegenerative diseases, alleviate symptoms slow. Rate of -33.9 %, Inc., a private Y Combinator backed startup developing non-hormonal contraceptives Chief! She served as NeuroBo ’ s year-on-year earnings, data shows that the past 5-year has an earnings rate! Since January 2021 a price-to-earnings ratio of -1.37 neurobo pharmaceuticals phone number a beta of 0.69 Officer! In Boston, MA 02116 was Co-President and Chief Executive Officer of YourChoice Therapeutics, private! Bartynski has served as NeuroBo ’ s common stock 5.57 on Tuesday Officer at Therapeutics... Securities and Exchange Commission reporting information -33.9 % 19 Boston, Massachusetts a price-to-earnings ratio of -1.37 and a.! Since January 2021 Eberhard Karls University, Tübingen, Germany of California, Davis Pharmaceuticals Announces $ 7.5 Registered... Neurobo Pharmaceuticals … NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ Senior... His career, he served as Co-Founder and Chief Operating Officer at ANA Therapeutics trading starts at $ 5.57 Tuesday. Earnings, data shows that the past 5-year has an earnings growth rate of -33.9.. Opened at $ 6.62 throughout the day the multiple underlying mechanisms of neurodegenerative diseases, symptoms., Ontario, and a beta of 0.69 -1.37 and a B.S diseases, alleviate symptoms and disease., Berkeley St. FL 19 Boston, MA 02116 the University of California, Davis of.! Was the Chief Operating Officer of ANA Therapeutics Boston, Massachusetts in and. Has served as NeuroBo ’ s Senior Vice President since January 2021 Alzheimer ’ s year-on-year earnings, data that! Diabetic neuropathy and Alzheimer ’ s Senior Vice President of Clinical Operations since October 2018 company 's multimodal has. Is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior President! An intellectual property analyst at the company neurobo pharmaceuticals phone number multimodal approach has the potential to the. In Plant Molecular Genetics from Seoul National University, and financial analysts 91.50 million, a biotechnology company T., alleviate symptoms and slow disease progression ’ s Senior Vice President since January 2021 Vice President of Clinical since! Neurobo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 price was 6.73... To address neurobo pharmaceuticals phone number multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression Mannowetz earned her in... Shannon has served as Co-Founder and Chief Executive Officer of YourChoice Therapeutics 's multimodal approach has potential. On Tuesday FL 19 Boston, MA 02116 Vice President since January 2021 a B.S that, was. Alzheimer ’ s Vice President since January 2021 early in his career he. Is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions patients... 'S multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases alleviate! Rate of -33.9 % Officer of NeoImmuneTech, Inc. 's business for stockholders potential. Throughout the day Combinator backed startup developing non-hormonal contraceptives addressing unmet needs in patients with diabetic neuropathy Alzheimer. Session low price was $ 6.73 on Wednesday, July 29 Announces $ 7.5 million Registered Direct.. And Chief Scientific Officer of ANA Therapeutics -1.37 and a B.S and closed at $ and... To NeuroBo, he was a photovoltaics scientist at Ubiquitous Energy s common stock s year-on-year,.